EcoR1 Capital
Latest statistics and disclosures from EcoR1 Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are APLS, PRTA, SRPT, ANAB, CRNX, and represent 39.20% of EcoR1 Capital's stock portfolio.
- Added to shares of these 10 stocks: MORF (+$89M), JANX (+$62M), CRGX (+$24M), ITOS (+$19M), BCYC (+$18M), TECX (+$14M), RCKT (+$11M), APLS (+$9.6M), REPL (+$7.7M), ATRA.
- Started 7 new stock positions in CRGX, REPL, JANX, RCKT, TECX, BCYC, ATRA.
- Reduced shares in these 10 stocks: SRPT (-$81M), ACAD (-$76M), ALEC (-$24M), NKTX (-$22M), OVID (-$19M), KURA (-$14M), GOSS (-$11M), KOD (-$8.8M), Atara Biotherapeutics (-$7.1M), ARQT.
- Sold out of its positions in ALEC, Alpine Immune Sciences, ARQT, Atara Biotherapeutics, GOSS, KOD, NKTX, OVID, PMVP.
- EcoR1 Capital was a net seller of stock by $-14M.
- EcoR1 Capital has $3.3B in assets under management (AUM), dropping by -17.32%.
- Central Index Key (CIK): 0001587114
Tip: Access up to 7 years of quarterly data
Positions held by EcoR1 Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for EcoR1 Capital
EcoR1 Capital holds 55 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals (APLS) | 13.6 | $445M | +2% | 12M | 38.36 |
|
| Prothena Corp SHS (PRTA) | 7.3 | $239M | 12M | 20.64 |
|
|
| Sarepta Therapeutics (SRPT) | 6.8 | $222M | -26% | 1.4M | 158.00 |
|
| Anaptysbio Inc Common (ANAB) | 5.8 | $189M | 7.5M | 25.06 |
|
|
| Crinetics Pharmaceuticals In (CRNX) | 5.7 | $186M | 4.2M | 44.79 |
|
|
| Arvinas Ord (ARVN) | 5.5 | $179M | 6.7M | 26.62 |
|
|
| Morphic Hldg (MORF) | 5.2 | $170M | +108% | 5.0M | 34.07 |
|
| Galapagos Nv Spon Adr (GLPG) | 4.4 | $143M | 5.8M | 24.78 |
|
|
| Kura Oncology (KURA) | 3.7 | $120M | -10% | 5.8M | 20.59 |
|
| Tango Therapeutics (TNGX) | 3.5 | $114M | 13M | 8.58 |
|
|
| Zymeworks Del (ZYME) | 3.5 | $114M | 13M | 8.51 |
|
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 3.3 | $108M | 1.0M | 106.73 |
|
|
| Xencor (XNCR) | 3.1 | $101M | 5.3M | 18.93 |
|
|
| Crispr Therapeutics Namen Akt (CRSP) | 2.3 | $75M | 1.4M | 54.01 |
|
|
| Janux Therapeutics (JANX) | 1.9 | $62M | NEW | 1.5M | 41.89 |
|
| Nuvation Bio Com Cl A (NUVB) | 1.7 | $56M | 19M | 2.92 |
|
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 1.6 | $52M | 5.7M | 9.03 |
|
|
| Iteos Therapeutics (ITOS) | 1.5 | $48M | +62% | 3.2M | 14.84 |
|
| Immunome (IMNM) | 1.4 | $47M | 3.9M | 12.10 |
|
|
| Neurogene (NGNE) | 1.4 | $46M | 1.3M | 36.39 |
|
|
| Third Harmonic Bio (THRD) | 1.3 | $41M | 3.2M | 13.00 |
|
|
| Mersana Therapeutics (MRSN) | 1.2 | $39M | 19M | 2.01 |
|
|
| Voyager Therapeutics (VYGR) | 0.9 | $31M | 3.9M | 7.91 |
|
|
| Avidity Biosciences Ord (RNA) | 0.9 | $31M | 758k | 40.85 |
|
|
| Tscan Therapeutics (TCRX) | 0.9 | $29M | 5.0M | 5.85 |
|
|
| Adaptimmune Therapeutics Sponds Adr (ADAP) | 0.8 | $27M | 27M | 0.97 |
|
|
| Oric Pharmaceuticals (ORIC) | 0.7 | $24M | 3.4M | 7.07 |
|
|
| Cargo Therapeutics (CRGX) | 0.7 | $24M | NEW | 1.5M | 16.42 |
|
| Celldex Therapeutics Com New (CLDX) | 0.7 | $24M | 650k | 37.01 |
|
|
| Vaxcyte (PCVX) | 0.7 | $23M | 300k | 75.51 |
|
|
| Edgewise Therapeutics (EWTX) | 0.7 | $23M | 1.3M | 18.01 |
|
|
| ACADIA Pharmaceuticals (ACAD) | 0.7 | $22M | -77% | 1.3M | 16.25 |
|
| Lenz Therapeutics (LENZ) | 0.6 | $21M | 1.2M | 17.29 |
|
|
| Madrigal Pharmaceuticals (MDGL) | 0.6 | $21M | 75k | 280.16 |
|
|
| Neumora Therapeutics (NMRA) | 0.6 | $20M | 2.1M | 9.83 |
|
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 0.6 | $18M | NEW | 910k | 20.24 |
|
| Atea Pharmaceuticals (AVIR) | 0.6 | $18M | -11% | 5.4M | 3.31 |
|
| Pharvaris N V (PHVS) | 0.5 | $17M | 900k | 18.80 |
|
|
| Dyne Therapeutics (DYN) | 0.5 | $15M | 427k | 35.29 |
|
|
| Tectonic Therapeutic Com Added (TECX) | 0.4 | $14M | NEW | 849k | 16.47 |
|
| Rocket Pharmaceuticals (RCKT) | 0.3 | $11M | NEW | 508k | 21.53 |
|
| Keros Therapeutics (KROS) | 0.3 | $8.6M | 188k | 45.70 |
|
|
| Allovir (ALVR) | 0.2 | $8.2M | 11M | 0.72 |
|
|
| Replimune Group (REPL) | 0.2 | $7.7M | NEW | 850k | 9.00 |
|
| Verve Therapeutics (VERV) | 0.2 | $6.1M | 1.3M | 4.88 |
|
|
| Generation Bio (GBIO) | 0.2 | $5.8M | 2.0M | 2.82 |
|
|
| Prime Medicine (PRME) | 0.1 | $3.6M | 700k | 5.14 |
|
|
| Atara Biotherapeutics Com New Added (ATRA) | 0.1 | $3.5M | NEW | 407k | 8.50 |
|
| Proqr Thrapeutics N V Shs Euro (PRQR) | 0.1 | $3.4M | -29% | 2.0M | 1.66 |
|
| Hookipa Pharma Inc equity | 0.1 | $3.4M | +24% | 5.7M | 0.59 |
|
| Kyverna Therapeutics (KYTX) | 0.1 | $3.4M | 450k | 7.50 |
|
|
| Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.1 | $2.8M | 963k | 2.92 |
|
|
| Aligos Therapeutics (ALGS) | 0.1 | $2.2M | 6.4M | 0.35 |
|
|
| Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $730k | 67k | 10.95 |
|
|
| Caremax *w Exp 06/08/202 (CMAXW) | 0.0 | $279k | 100k | 2.79 |
|
Past Filings by EcoR1 Capital
SEC 13F filings are viewable for EcoR1 Capital going back to 2014
- EcoR1 Capital 2024 Q2 filed Aug. 14, 2024
- EcoR1 Capital 2024 Q1 filed May 15, 2024
- EcoR1 Capital 2023 Q4 filed Feb. 14, 2024
- EcoR1 Capital 2023 Q3 filed Nov. 14, 2023
- EcoR1 Capital 2023 Q2 filed Aug. 14, 2023
- EcoR1 Capital 2023 Q1 filed May 15, 2023
- EcoR1 Capital 2022 Q4 filed Feb. 14, 2023
- EcoR1 Capital 2022 Q3 filed Nov. 14, 2022
- EcoR1 Capital 2022 Q2 filed Aug. 15, 2022
- EcoR1 Capital 2022 Q1 filed May 16, 2022
- EcoR1 Capital 2021 Q4 filed Feb. 14, 2022
- EcoR1 Capital 2021 Q3 restated filed Nov. 22, 2021
- EcoR1 Capital 2021 Q3 filed Nov. 15, 2021
- EcoR1 Capital 2021 Q2 filed Aug. 16, 2021
- EcoR1 Capital 2021 Q1 filed May 17, 2021
- EcoR1 Capital 2020 Q4 filed Feb. 16, 2021